Therapeutic Solutions International Identifies Novel Cellular Marker Associated with Therapeutic Response to JadiCell Stem Cell Treatment

Rhea-AI Summary

Therapeutic Solutions International (TSOI) has announced a significant discovery in stem cell therapy by identifying a specific type of B cell, producing interleukin-10, that may predict responsiveness to JadiCell therapy. This finding could enhance personalized medicine in regenerative treatments. The company is currently conducting a Phase III clinical trial for COVID-19 ARDS and has received INDs for using JadiCells in COPD and Chronic Traumatic Encephalopathy. The clinical relevance of this marker may extend beyond JadiCells, potentially advancing the effectiveness of stem cell therapies.

Positive

• Identification of a predictive marker for efficacy in JadiCell therapy.
• Ongoing Phase III clinical trial for COVID-19 ARDS.
• IND approvals for use in COPD and Chronic Traumatic Encephalopathy.

Negative

• None.

New Finding May Facilitate Personalized Stem Cell Therapy

ELK CITY, Idaho--(BUSINESS WIRE)-- Therapeutic Solutions International (TSOI) announced today identification and patent filing of a previously unexpected discovery that responsiveness to JadiCell stem cell therapy appears to correlate with alternations of a specific type of B cell producing the cytokine interleukin-10 and possessing unique surface markers.

These types of B cells, which are related to a cell type previously associated with pregnancy, appear to play a role in controlling pathological immunity, as well as producing factors that may be involved in healing injured tissues.

Therapeutic Solutions International has a Phase III clinical trial ongoing for COVID-19 acute respiratory distress syndrome (ARDS) and has been granted IND numbers for use of JadiCells in Chronic Obstructive Pulmonary Disease (COPD) and Chronic Traumatic Encephalopathy. Additionally, the Company has active, ongoing, collaborations with physicians to provide the cells under Emergency IND and Right to Try.

“As a Principal Investigator for these clinical trials, it is difficult to overstate how important it is to possess a marker that appears to predict responsiveness to our stem cell therapy,” said Dr. James Veltmeyer, Chief Medical Officer of the Company, and co-inventor of the patent. “From preliminary data in patients, and also in our laboratory research, it appears that this marker may be predictive for efficacy of other stem cells besides JadiCells.”

“The field of biotechnology in general is aiming for the Holy Grail called 'Personalized Medicine'. The findings disclosed today, we feel, bring Personalized Medicine to the area of Regenerative Medicine and Regenerative Psychiatry,” said Timothy Dixon, President, and CEO of the Company and co-inventor. “Significant sums of money are routinely spent on clinical trials that do not provide efficacy data. Many believe that this occurs simply because we are not choosing the right patients. It is reasonable to believe that if today’s results are reproducible on a larger scale, we will possess a new tool to advance the field of stem cell sciences.”

About Therapeutic Solutions International, Inc.

Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company's corporate website is www.therapeuticsolutionsint.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230109005494/en/

Timothy G. Dixon

ir@tsoimail.com

Source: Therapeutic Solutions International, Inc.

FAQ

What recent discovery did Therapeutic Solutions International (TSOI) announce?

TSOI announced the identification of a B cell type that may predict responsiveness to JadiCell stem cell therapy.

How does the new finding impact personalized medicine?

It may facilitate personalized approaches in regenerative medicine by identifying a marker for treatment efficacy.

What clinical trials is Therapeutic Solutions International currently conducting?

TSOI is conducting a Phase III clinical trial for COVID-19 acute respiratory distress syndrome.

What are the implications of the B cell marker for stem cell therapies?

The marker may not only predict efficacy for JadiCells but could also be applicable to other stem cell therapies.